TY - JOUR
T1 - Dengue and COVID-19 Co-Circulation in the Peruvian Amazon
T2 - A Population-Based Study
AU - Pons, Maria J.
AU - Mayanga-Herrera, Ana
AU - Ulloa, Gabriela M.
AU - Ymaña, Barbara
AU - Medina, Sabrina
AU - Alava, Freddy
AU - Alvarez-Antonio, Carlos
AU - Meza-Sanchez, Graciela
AU - Calampa, Carlos
AU - Casanova, Wilma
AU - Carey, Cristiam
AU - Rodrıguez-Ferrucci, Hugo
AU - Morrison, Amy C.
AU - Quispe, Antonio M.
N1 - Publisher Copyright:
Copyright © 2023 The author(s).
PY - 2023
Y1 - 2023
N2 - The COVID-19 pandemic affected the main Amazon cities dramatically, with Iquitos City reporting the highest seroprevalence of anti-SARS-CoV-2 antibodies during the first COVID-19 wave worldwide. This phenomenon raised many questions about the possibility of a co-circulation of dengue and COVID-19 and its consequences. We carried out a population-based cohort study in Iquitos, Peru. We obtained a venous blood sample from a subset of 326 adults from the Iquitos COVID-19 cohort (August 13–18, 2020) to estimate the seroprevalence of anti-dengue virus (DENV) and anti-SARS-CoV-2 antibodies. We tested each serum sample for anti-DENV IgG (serotypes 1, 2, 3, and 4) and SARS-CoV-2 antibodies anti-spike IgG and IgM by ELISA. We estimated an anti-SARS-CoV-2 seroprevalence of 78.0% (95% CI, 73.0–82.0) and an anti-DENV seroprevalence of 88.0% (95% CI, 84.0–91.6), signifying a high seroprevalence of both diseases during the first wave of COVID-19 transmission in the city. The San Juan District had a lower anti-DENV antibody seroprevalence than the Belen District (prevalence ratio, 0.90; 95% CI, 0.82–0.98). However, we did not observe these differences in anti-SARS-CoV-2 antibody seroprevalence. Iquitos City presented one of the highest seroprevalence rates of anti-DENV and anti-SARS-CoV-2 antibodies worldwide, but with no correlation between their antibody levels.
AB - The COVID-19 pandemic affected the main Amazon cities dramatically, with Iquitos City reporting the highest seroprevalence of anti-SARS-CoV-2 antibodies during the first COVID-19 wave worldwide. This phenomenon raised many questions about the possibility of a co-circulation of dengue and COVID-19 and its consequences. We carried out a population-based cohort study in Iquitos, Peru. We obtained a venous blood sample from a subset of 326 adults from the Iquitos COVID-19 cohort (August 13–18, 2020) to estimate the seroprevalence of anti-dengue virus (DENV) and anti-SARS-CoV-2 antibodies. We tested each serum sample for anti-DENV IgG (serotypes 1, 2, 3, and 4) and SARS-CoV-2 antibodies anti-spike IgG and IgM by ELISA. We estimated an anti-SARS-CoV-2 seroprevalence of 78.0% (95% CI, 73.0–82.0) and an anti-DENV seroprevalence of 88.0% (95% CI, 84.0–91.6), signifying a high seroprevalence of both diseases during the first wave of COVID-19 transmission in the city. The San Juan District had a lower anti-DENV antibody seroprevalence than the Belen District (prevalence ratio, 0.90; 95% CI, 0.82–0.98). However, we did not observe these differences in anti-SARS-CoV-2 antibody seroprevalence. Iquitos City presented one of the highest seroprevalence rates of anti-DENV and anti-SARS-CoV-2 antibodies worldwide, but with no correlation between their antibody levels.
UR - http://www.scopus.com/inward/record.url?scp=85163239919&partnerID=8YFLogxK
U2 - 10.4269/ajtmh.22-0539
DO - 10.4269/ajtmh.22-0539
M3 - Original Article
C2 - 37094790
AN - SCOPUS:85163239919
SN - 0002-9637
VL - 108
SP - 1249
EP - 1255
JO - American Journal of Tropical Medicine and Hygiene
JF - American Journal of Tropical Medicine and Hygiene
IS - 6
ER -
